Literature DB >> 12758214

Prospects for a better vaccine against tuberculosis.

S G Reed1, M R Alderson, W Dalemans, Y Lobet, Y A W Skeiky.   

Abstract

There have been many new promising approaches to developing human vaccines against tuberculosis (TB). Advances in gene and antigen identification, availability of genome sequences, a greater understanding of immune mechanisms in resistance to TB, the development of adjuvants and delivery systems to stimulate T-cell immunity, and increased funding from public and private agencies are some of the reasons for progress in this area. Dozens of vaccine candidates have been tested in animal models in recent years, and several of these are poised to move into clinical trials in the next several years. Thus, there is renewed optimism for the potential of developing new and improved TB vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12758214     DOI: 10.1016/s1472-9792(02)00080-x

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  13 in total

1.  Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.

Authors:  Teresa M Wozniak; Anthony A Ryan; James A Triccas; Warwick J Britton
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  Aptamer inhibits Mycobacterium tuberculosis (H37Rv) invasion of macrophage.

Authors:  Fan Chen; Xiaolian Zhang; Jing Zhou; Shengwu Liu; Junyan Liu
Journal:  Mol Biol Rep       Date:  2011-06-04       Impact factor: 2.316

3.  Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.

Authors:  Dongmei Lu; Lucila Garcia-Contreras; Pavan Muttil; Danielle Padilla; Ding Xu; Jian Liu; Miriam Braunstein; David N McMurray; Anthony James Hickey
Journal:  AAPS J       Date:  2010-04-27       Impact factor: 4.009

4.  Construction of an Expression Vector Containing Mtb72F of Mycobacterium tuberculosis.

Authors:  Maryam Sadat Nabavinia; Mahboobeh Naderi Nasab; Zahra Meshkat; Mohammad Derakhshan; Mehrangiz Khaje-Karamadini
Journal:  Cell J       Date:  2012-06-13       Impact factor: 2.479

5.  Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

Authors:  Steven G Reed; Rhea N Coler; Wilfried Dalemans; Wilifred Dalemans; Esterlina V Tan; Eduardo C DeLa Cruz; Randall J Basaraba; Ian M Orme; Yasir A W Skeiky; Mark R Alderson; Karen D Cowgill; Jean-Paul Prieels; Rodolfo M Abalos; Marie-Claude Dubois; Joe Cohen; Pascal Mettens; Yves Lobet
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-02       Impact factor: 11.205

6.  DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: implications for vaccine efficacy.

Authors:  Andrea M Hebert; Sarah Talarico; Dong Yang; Riza Durmaz; Carl F Marrs; Lixin Zhang; Betsy Foxman; Zhenhua Yang
Journal:  Infect Immun       Date:  2007-09-24       Impact factor: 3.441

7.  The reinfection threshold promotes variability in tuberculosis epidemiology and vaccine efficacy.

Authors:  M Gabriela M Gomes; Ana O Franco; Manuel C Gomes; Graham F Medley
Journal:  Proc Biol Sci       Date:  2004-03-22       Impact factor: 5.349

8.  Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning.

Authors:  Rhea N Coler; Davin C Dillon; Yasir A W Skeiky; Maria Kahn; Ian M Orme; Yves Lobet; Steven G Reed; Mark R Alderson
Journal:  Vaccine       Date:  2008-11-08       Impact factor: 3.641

9.  Effect of skin testing and segregation on the prevalence of bovine tuberculosis, and molecular typing of Mycobacterium bovis, in Ethiopia.

Authors:  G Ameni; A Aseffa; A Sirak; H Engers; D B Young; R G Hewinson; M H Vordermeier; S V Gordon
Journal:  Vet Rec       Date:  2007-12-08       Impact factor: 2.695

10.  Immunogenicity of recombinant Mycobacterium bovis bacille Calmette-Guèrin clones expressing T and B cell epitopes of Mycobacterium tuberculosis antigens.

Authors:  Rohimah Mohamud; Maryam Azlan; Daniel Yero; Nadine Alvarez; Maria E Sarmiento; Armando Acosta; Mohd-Nor Norazmi
Journal:  BMC Immunol       Date:  2013-02-25       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.